Cornea

Treatment slows or halts the progression of keratoconus, corneal ectasia

Question of which technique is superior remains unanswered amid shift to thinner grafts

Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment 

Providing findings from a retrospective study, Li Lim, MD, noted that eyes with high myopia benefit from CXL add-on to LASIK, resulting in safety, efficacy, and predictability with refractive outcomes that are more stable than those achieved with LASIK alone. 

With ‘surprise’ finding, results may help indicate future corneal pathology that may occur

Adding procedure can improve visual function, offer patients normal lifestyle

Novel technique could help surgeons treating keratoconus, ectasia

Stabilization, improvement in corneal curvature measurements seen in many treated cases

Combining LASIK, corneal inlays hits refractive ‘sweet spot’ for many patients

Quantitative measurement indicates corneal epithelium plays crucial role in outcomes

Management evolves from nasal neurostimulation, prosthetic replacement of ocular surface ecosystem

CXL has potential to alter disease course; progression display plays role in when to intervene

Ophthalmology Times’ Editorial Advisory Board members share their thoughts on what to watch in year ahead

Evaluate patients’ social situations; educate parents about their participation

Erin D. Stahl, MD, discusses why it's important to diagnose and treat children with keratoconus at the earliest signs of development for successful outcomes during the AAO 2018 meeting in Chicago.

A study of patients undergoing corneal crosslinking (CXL) for keratoconus suggests gene expression and tear inflammatory profile may be used as biomarkers to predict CXL outcomes.

Shortcomings in ablative procedures mean that new developments in refractive surgery are welcome. Arthur Cummings, MD, FRCSEd, reviews two new technologies that will increase patient satisfaction.

Topical cenegermin has been approved by the FDA for the treatment of moderate-to-severe neurotrophic keratitis (NK), ushering in a breakthrough of management.